Send to

Choose Destination
Adv Drug Deliv Rev. 2006 Oct 31;58(9-10):1106-18. Epub 2006 Aug 12.

Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway.

Author information

Syntonix Pharmaceuticals, 9 Fourth Avenue, Waltham, MA 02451, USA.


We have applied a "physiologic" approach to the pulmonary delivery of therapeutic proteins, utilizing an immunoglobulin (antibody) transport pathway recently shown to be present predominantly in the conducting airways of the human respiratory tract. Therapeutic proteins are fused to the Fc-domain of an IgG1, allowing them to bind with high affinity to the antibody transport receptor, FcRn. Liquid aerosols are administered into the lung using normal breathing maneuvers and efficient delivery of several different Fc-fusion proteins has been achieved with retention of biological activity and an increase in circulating half-life. A new paradigm for the pulmonary delivery of therapeutic proteins and a fundamental advance in the construction of Fc-fusion proteins for this purpose will be described.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center